Contact this trialFirst, we need to learn more about you.
Iron Chelator
Deferoxamine for Meningeal Carcinomatosis
Recruiting1 awardPhase 1
New York, New York
This trial is testing the safety of giving deferoxamine (DFO) directly into the CSF to treat leptomeningeal metastasis from solid tumor cancer. The researchers will start with lower doses and increase until they find the highest dose that still causes few or mild side effects. If DFO is found to be safe, the researchers will then test it to see if it is an effective treatment for NSCLC.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.